Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | The DUO trial: dose modifications on response to duvelisib in patients with SLL/CLL

Paolo Ghia • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Duvelisib
DUO

Paolo Ghia, MD, PhD, IRCCS, San Raffaele Scientific Institute, Milan, Italy, talks about the DUO trial (NCT02004522) looking at the effect of dose modifications on the response to duvelisib in patients with SLL/CLL. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals